

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (canceled).

4. (currently amended) A vector comprising the nucleic acid molecule of any one of claims ~~1 or 90-96~~ 99-101.

5. (currently amended) A host cell comprising the nucleic acid molecule of any one of claims ~~1 or 90-96~~ 99-101.

6. (currently amended) A host cell comprising the nucleic acid molecule of any one of claims ~~1 or 90-96~~ 99-101 operatively linked to a regulatory sequence other than the promoter for a native IL-17 receptor like polypeptide.

7. (previously presented) A host cell modified by transformation or transfection with a regulatory nucleic acid, wherein said regulatory nucleic acid promotes transcription or translation of a nucleic acid comprising the sequence of SEQ ID NO: 1, 4, or 6.

8. (original) The host cell of claim 7 wherein the regulatory nucleic acid sequence is a promoter.

9. (original) The host cell of claim 7 wherein the regulatory nucleic acid is a transcription factor.

10. (previously presented) The host cell of claim 5 that is a eukaryotic cell.

11. (previously presented) The host cell of claim 5 that is a prokaryotic cell.

12. (currently amended) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of ~~any one of claims 5, 6 or 7~~ claim 5 under

suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

Claim 13 (canceled).

14. (currently amended) The process of ~~claim any one of claims 12, 97 and 98~~ wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native IL-17 receptor like polypeptide operatively linked to the DNA encoding the IL-17 receptor like polypeptide.

Claims 15-58 (canceled).

59. (currently amended) A composition comprising a nucleic acid molecule of any one of claims ~~1 or 90-96~~ 99-101 and a pharmaceutically acceptable formulation agent.

60. (previously presented) A composition of claim 59 wherein said nucleic acid molecule is contained in a viral vector.

61. (currently amended) A viral vector comprising a nucleic acid molecule of any one of claims ~~1 or 90-96~~ 99-101.

Claims 62-73 (canceled).

74. (previously presented) A diagnostic reagent comprising a detectably labeled polynucleotide encoding the amino acid sequence set out in at least one of SEQ ID NO: 2, SEQ ID NO: 5 or SEQ ID NO: 7.

75. (original) The diagnostic reagent of claim 74, wherein said labeled polynucleotide is a first-strand cDNA.

Claims 76-90 (canceled).

91. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence that is at least 90% identical to of any one of claims 99-101 wherein the nucleic acid molecule of ~~claim 1~~ and encodes a polypeptide that induces inflammation.

92. (currently amended) An isolated nucleic acid molecule comprising a nucleic acid sequence that is at least 90% identical to of any one of claims 99-101 wherein the nucleic acid molecule of ~~claim 1~~ and encodes a polypeptide that induces myelopoiesis.

Claims 93-96 (canceled).

97. (new) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 6 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

98. (new) A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 7 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

99. (new) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising nucleotides 50 through 1555 of SEQ ID NO: 1;

(b) a nucleotide sequence comprising nucleotides 50 through 925 of SEQ ID NO: 1;

(c) a nucleotide sequence comprising nucleotides 89 through 925 of SEQ ID NO: 1;

(d) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 502 of SEQ ID NO: 2;

(e) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 292 of SEQ ID NO: 2;

(f) a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 292 of SEQ ID NO: 2;

(g) a nucleotide sequence encoding a polypeptide comprising a fragment of amino acids 14 through 292 of SEQ ID NO: 2, wherein the polypeptide fragment binds IL-17;

(h) a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 292 of SEQ ID NO: 2, wherein the polypeptide binds IL-17; and

(i) a nucleotide sequence fully complementary to any of (a)-(g).

100. (new) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising nucleotides 50 through 1729 of SEQ ID NO: 4;

(b) a nucleotide sequence comprising nucleotides 50 through 1099 of SEQ ID NO: 4;

(c) a nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4;

(d) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 560 of SEQ ID NO: 5;

(e) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 350 of SEQ ID NO: 5;

(f) a nucleotide sequence encoding a polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5;

(g) a nucleotide sequence encoding a polypeptide comprising a fragment of amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide fragment binds IL-17;

(h) a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17; and

(i) a nucleotide sequence fully complementary to any of (a)-(g).

101. (new) An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

(a) a nucleotide sequence comprising nucleotides 273 through 1427 of SEQ ID NO: 6;

(b) a nucleotide sequence comprising nucleotides 273 through 797 of SEQ ID NO :6;

(c) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 385 of SEQ ID NO: 7;

(d) a nucleotide sequence encoding a polypeptide comprising amino acids 1 through 175 of SEQ ID NO: 7;

(e) a nucleotide sequence encoding a polypeptide comprising a fragment of amino acids 1 through 175 of SEQ ID NO: 7, wherein the polypeptide fragment binds IL-17;

(f) a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 1 through 175 of SEQ ID NO: 7, wherein the polypeptide binds IL-17; and

(g) a nucleotide sequence fully complementary to any of (a)-(c).

102. (new) An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of an amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3176.

103. (new) An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of an amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3177.

104. (new) An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of an amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3178.